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Although complement is often detected in the intercel-
lular substance of pemphigus skin lesions, the ability of 
pemphigus antibodies to fix complement in vitro is con-
troversial. The purpose of this study was to test. in vitro 
complement fixation abilities of pemphigus antibodies 
further using organ and tissue culture methods. Epider-
mal cell monolayers from mouse tail were incubated 
with the purified lgG fraction of pemphigus serum fol-
lowed by purified Clq. Binding of Clq, as well as lgG 
was demonstrated by immunofluorescence methods. 
When purified Clq was replaced with normal human 
serum as a complement source, positive C3 and C4 stain-
ing were also evident. When purified lgG of normal 
human serum was used in place of pemphigus IgG, sim-
ilar immunofluorescence staining was not observed. 
Further evidence for complement fixation in vitro by 
pemphigus antibodies was obtained using organ cul-
tures. Organ culture of normal human skin and monkey 
esophageal mucosa cultured in purified pemphigus IgG 
showed intercellular substance binding of IgG. No bind-
ing was observed when normal lgG was substituted for 
pemphigus IgG. Additional organ culture sections were 
then treated with complement (fresh normal human 
serum) and tested by in vitro complement staining. Fix-
ation of Clq, C4, and C3 was noted in intercellular 
substance areas of organ cultured skin and mucosa in-
cubated with pemphigus lgG but not those incubated 
with normal IgG. Prior treatment of pemphigus IgG 
organ cultured skin sections with unlabeled anti-C3, 
blocked positive C3 staining. These results suggest that 
some pemphigus antibodies are capable of activating 
complement in vitro. 
Previous studies have implicated the complement system in 
t he pathogenesis of a number of bullous skin diseases including 
bullous pemphigo id, cicatricial pemphigoid, and herpes gesta-
tionis [1]. Despite t he presence of lgG class autoantibodies 
reactive with an intercellu lar substance (ICS) of skin and 
mucosa in serum samp les of patients with pemphigus [2,3], the 
ability of these antibodies for activating the complement system 
has remained controversial. ln a n early study, Jordon et al [4) 
Manuscript rece ived October 13, 1983; accepted for publication 
January 13, 1984. 
Supported in part by research grants Al-14550, AM -32974, and the 
Veterans Administration . 
Reprint requests to: Robert E. Jordon , M.D., Department of Der-
matology, The University of T exas Health Science Center, 6431 Fan-
nin, Su ite 1204, Houston, Texas 77030. 
Abbreviations: 
FITC: fluorescei n isothiocya nate 
HBSS: Hanks' balanced salt solution 
ICS: intercellula r substance 
IF: immunofluorescence 
lgG: gamma globulin 
NHS: normal human se rum 
VBS++ : veronal-buffered sa line co ntaining 0.5 mM magnesium 
chloride and 0.15 mM calcium chloride 
failed to demonstra te that pemphigus a ntibodies would fix 
complement despite the fac t that they are found in IgG sub-
classes normally associated with complement activation [ 5] and 
the fac t that complement deposits are routinely found in acan-
tholytic areas of pemphigus skin les ions by direct immunoflu-
orescence (IF) staining [6- 8] . Later, Nis hikawa and coworkers 
[9 ,10) were able to show that some pemphigus sera would fix 
complement to ICS areas of skin using in vitro C3 IF staining. 
As a variety of cont1icting theories have evolved to explain 
Nishikawa's findings , including participation of other serum 
factors, we undertook the present studies in an attempt to 
resolve the issue . Using organ and tissue cul ture methods, which 
mimic acantholysis in vitro, and purified l gG fractions , we have 
tested the complement-fixing abilities of p emphigus antibodies 
further. 
MATERIALS AND METHODS 
Jmmuno,globulin Fractions 
Sera from 2 patients with pemphigus vulga ris were obtained by 
plasmapheresis. These patients had pemphigus antibody Liters of 640 
(patient 1) and 160 (patient 2) using monkey esophagus as tissue 
substrate. Serum from a healt hy donor and pooled normal human 
serum (NHS) (Gibco Laboratories, Grand fs land, New York) served as 
cont rols. IgG purification of heat- inactivated normal and patient serum 
(56' C, 30 min ) was performed by precipitation with 50% saturated 
ammonium sulfate followed by chromatography of DEAE-cellulose 
(DE52, Whatman, Clifton, New J ersey) wi th 0.01 M Tris buffe r at pH 
8.0. The fractions of the first peak were collected, dialyzed against 3 
changes of distilled H20 at 4 ' C, lyophilized, and stored at -20' C. 
Sources of Complement 
Fresh NHS was obtained from a healthy individual wi th AB blood 
type for complement binding studies in organ culture, and for t he 
absorbed NH S used in the tissue culture. Absorption of NHS was 
carried out by t he following step to remove antibody to substances of 
mouse epidermal cell surface. The cells obtained from mouse tails were 
suspended in 2 ml of fresh NHS at 37'C for 2 h and incubated at. 4' C 
overnight with gentle shaking. After centrifugation at 2000 rpm for 20 
min, the absorbed serum from the supernate was collected and stored 
at -70' C. 
By hemolytic complement assay, the CHr.o of absorbed NHS was 52 
units. C2-delicient serum used in control studies was also absorbed in 
a similar fashion. 
Clq was purified from fresh NHS according to the met hod described 
by Yonemasu and Stroud [11] wi t h minor modilications [1 2]. Purity 
was checked by double immunodiffusion (Ouchterlony); protein con-
centra tion was estimated by reading on a spectrophotometer at 280 
nm. Purified Clq was a lso used as a source of complemen t in some of 
our studies. 
Antiserum 
506 
Unlabeled antiserum to C3 component of complement was prepared 
by the methods previously outlined in deta il [1 3]. Monospecilic anti-
serum to human lgG was prepared by injecting goats with a DEAE 
cellulose purified gamma globulin (lgG), followed by purification by 
affinity chromatography using human lgG coupled to Sepharose 48 
(Pharmacia Fine Chemicals, Uppsala, Sweden). The monospecific anti-
serum was t hen conjugated with fluorescei n isothiocyanate (FITC). 
FITC-labeled goat antihuman Clq, C4 , and C3 serum were purchased 
(Meloy Laboratories, Inc., Springfield, Virginia) and tested for sensi-
t ivity by previously desc ribed methods [8,13]. 
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Epidermal Keralinocyte Culture 
Epidermal cells from adult. mouse were cultured using a modification 
of the technique of Brysk et al [ 14 [. Briefly, the tai l skin removed from 
adult mouse (C3H, DBA/ 2) was placed for 1 h in an antibiotic solution 
contain ing 0.1 mg/ ml gentamycin su lfate (GRS Garamycin, Schering 
Co., Kenilworth, New Jersey), 75 U/ ml mycostatin (Gibco Laborato-
ries). and 400 IU pen ici llin -400 meg streptomycin/m l (Flow Laborat.o-
ries, McLean , Virgin ia) in Hanks' balanced salt solution (HBSS) (Flow 
Laborato ries) without Mg++ or Ca++. The tissue was then incubated 
in 0.5% trypsin in HBSS at 37"C for 1 h, and the dermis and epidermis 
were separated and processed by gent le teasi ng. The suspension was 
filtered through sterile gauze to eliminate skin and hair fragments and 
centrifuged at 1000 rpm for 10 min . The pellet was resuspended in 
· 0.002% DNase I (Sigma Chemical Co., St. Louis, Missouri) in Medium 
199 (modi tied) without calcium chloride (Flow Laboratories) for 1 hat 
room temperatu re, and separated on a discontinuous Percoll (Phar-
macia Fine Chemicals, Inc.) gradient (1.02, 1.04, l.OG, 1.07, 1.09 g/ cm") 
(2500 rpm, 20 min) . Cells were collected from the 1.07- 1.09 interface 
of the tube. After washing to remove Percoll , the cells were resuspended 
in Eagle's minimum essential medium with HBSS and Hepes (MA 
Bioproducts, Walkersville, Maryland) contai ning 10% fetal bovine 
serum (MA Bioproduct.s), 0.292 mg/ml L-glutamine (Gibco Laborato-
ries), 200 U penicillin- 200 meg streptomycin/ ml, and 0.03 mg/ ml 
gentamycin and then plated in co llagen (Vitrogen 100, Flow Labo ra-
to ries) -coated tissue culture chamber/slides (Miles Laboratories, Na -
persvi lle, Illinois) . The cells were cul tu red in 5% C02 at :37"C. T he 
medium was changed every 3 days. 
Organ Culture 
Organ culture was carried out by t he method of Sarkany et al [15] 
with modifications described by Schil tz and coworkers [1G]. Specimens 
of adult human skin from pat ients undergoing amputation , or monkey 
esophagus were cut to a thickness of 0.3 mm with Castroviejo electro-
keratome (Storz Surgical Instruments, St. Louis, Missouri). The sheets 
were cut in to squa res (approximately 2 X 2 mm), and a single squa re 
of skin was placed dermal side down on a larger square of steri le lens 
paper (approximately 1 cm 2). The edges of the paper were dipped in to 
molten paraffin wax. The paper rafts were l1oat.ed on the surface of the 
appropriate culture medium in culture dishes and placed in a humid 
atmosphere contai ning 5% C02 in air at 37"C. Control culture media 
consisted of heat-inactivated pooled NHS (Gibco), while test media 
consisted of heat-inactivated pooled NHS containing pemphigus lgG 
to a fin al concentration of 6.75 mg/ml (IF titer 1:128 patient I, 1:32 
patient 2 when tested on monkey esophagus). Cul tu red sk in was re-
moved after 48 h of incubation and was quick-frozen in liquid ni trogen 
and sto red at -70"C. 
1 mm.un.of/ uorescence P raced ures 
Epiderm al cell monolayers (5 days after plating) from mouse ta ils 
were incubated in phosphate-buffered sali ne containing 3 mg/ ml of 
pemphigus lgG (IF titer 1:80 patient 1, 1:20 patient 2 when tested on 
monkey esop hagus) or normal JgG. Then the cells were incubated with 
e ither 25 mg/ml of purified Clq dissolved in veronal-buffered saline 
containing 0.5 mM magnesium chloride and 0. 15 mM calcium chloride 
(VBS++) , or absorbed NHS diluted 1:10 in VBS++. As controls heat-
inactivated NHS at 56"C, 30 min, 15 mM Mg++ -EGTA or 10 mM 
EDT A-treated NHS were used in place of these complement sources. 
Additional control was the substitution of C2-deficient serum diluted 
1:10 in VBS++ which was absorbed on epidermal cells. JgG and 
complement binding were examined using FITC-goat antihuman IgG, 
Clq, C4, and C3 antisera . In addit ion, block ing of C3 staining was 
accomplished by prior incubation with unlabeled goat antihuman C3 
serum before IF staining. 
Organ cu lture specimens stored at -70"C were cryostat sectioned at 
4 I'm, mounted on glass slides, and ai r dried for 30 min. Slides were 
then incubated with fresh NHS or C2-deficient serum diluted 1:10 m 
VBS++. Controls were performed using heat-inactivated EDTA or 
Mg++- EGTA-treated NHS. lgG and complement binding were de-
tected using the above-mentioned conjugated antisera. 
Pemphigus and normal lgG fractions were also tested for fixation of 
C3 using cryostat sections of adu lt normal human skin and monkey 
esophagus by in vitro complement staining. 
RESULTS 
Treatment of cryostat sections of eit her normal huma n skin 
or m onkey esophagus with the IgG fraction from pemphigus 
patient 1 resulted in positive C3 staining of the ICS. Similar, 
but minimal ICS staining was observed using t he lgG fraction 
from pemphigus patient 2, whereas no stain ing was observed 
using the normal IgG fract ion. The positive ICS staining reac-
tions observed using pemphigus IgG fractions on these normal 
t issues, however, was less intense than the staining reactions 
which resulted from the procedures described below. 
Mouse epidermal cells covered approximately 80% of the 
surface of the cul ture sl ide by day 3, a nd a complete monolayer 
was formed by day 5. By direct IF staining, the monolayer cells 
treated with pemphigus IgG from patient 1 showed granular 
staining (speckled pattern) of the cell surface when treated 
with FITC-labeled an ti human lgG. W hen purified Clq was 
added as a source of complement, staining with a simi lar 
speck led pattern was noted (Fig la) by in vitro Clq IF staining. 
When purified Clq was replaced by absorbed NHS as the source 
of complement, C3 and C4.as well as Clq binding were observed 
(Fig lb) by in vitro Clq, C3, and C4 staining. On t he other 
hand, ne ither IgG nor complement (Clq, C4, and C3) binding 
was obse rved on cell surfaces t reated wit h lgG fractions of NHS 
(fig lc). When cul tured epidermal cells were t reated with t he 
IgG fract ion of pemphigus patient 2 and tested for Clq, C4, and 
C3 binding in a similar manner, the staining patterns observed 
were identical to those obtained with patient 1. The staining, 
however, was less intense. 
To determine t he mode of fixation of complement by pem-
phigus lgG, selected cont rol tests were performed using t he JgG 
fraction from patient 1 (Table I). As noted previously, positive 
Clq, C4, and C3 stain ing occurred when NHS was used as the 
source of complement , whereas on ly positive Clq stain ing was 
obse rved when purified Clq was used as t he complement source. 
Heat inactivation of t he complement source resulted in inhi-
bition of a ll 3 complement staining reactions. Treatment of t he 
complement source with EDTA decreased t he intensity of Clq 
staining while completely inhibi t ing both C4 and C3 staining. 
When Mg++- EGTA was added to t he complement source, 
partial inhibition of Clq and C4 staining occurred, while C3 
staining was again completely inhibited. Partial inhibition of 
t he Clq and C4 staining reactions, when chelators are added to 
th e complement source, is co nsistent with our previous obser-
vations [17,18]. Substit ution of C2-deficient serum as the 
source of complement a lso yielded negative C3 sta ining but 
positive Clq and C4 staining (Fig 2). In addition, prior treat-
ment with unlabeled an ti-C3 antiserum blocked positive C3 
staining. 
Further evidence for complemen t. fixation in vitro by pem-
phigus IgG was obtained using organ cultured skin specimens. 
IgG binding was observed in the ICS areas of both human skin 
a nd monkey esophagea l orga n culture specimens after a 48-h 
cul t ivation with t he pemphigus IgG fractions. At 48 h , minimal 
or early evidence of acantholysis was appa rent in t he spec imens. 
Clq, C4, and C3 staining reactions were noted in the ICS areas 
of these explan ts when cryostat sections were treated with 
complement (fresh NHS) and labeled antisera to Clq, C4, and 
C3 (Fig 3) . The same control reaction patterns, as described 
for t he cultured mouse epidermal cells, were noted when the 
sections of organ cultured human skin were t reated with C2-
deficient serum, heat- inactivated NHS, or NHS treated with 
either EDTA or Mg++- EGTA. Prior treatment of the comple-
ment-treated organ cul tured skin sections with unlabeled anti -
C3 resulted in blocking of t he positive C3 staining. When organ 
cul tures were cul tivated with normal lgG, rather than with 
pemphigus lgG, no positive complement sta in ing reactions were 
noted. 
DISCUSSION 
As noted earlier , t he ability of pemphigus antibodies to fix 
complement has been t he subject of considerable debate. For 
many yea rs, t hese ant ibodies were thought to be non-comple-
ment fixing. The fact t hat complement components are rou-
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tin ely found deposited in pemphigus skin lesions led Nishikawa, 
Hashimoto, and coworkers [9,10] to reinvestigate t hi s phenom-
enon further some years later. T heir pos itive findin gs, however, 
have only led to more cont roversy, leading some to suggest t hat 
other serum facto rs, such as rheumato id factors, might account 
for the observed complement fixation. 
In an attempt to resolve t hi s controversy, we chose to use 
purified IgG fractions of both pemphigus and normal human 
se rum . Since heavy deposition of various complement compo-
nents is seen in areas of aca ntholysis but not in normal-
appea ring areas of pemphigus skin [6- 8]. we a lso chose to use 
Vol. 82, No. 5 
FIG 1. Mouse epidermal mo nolaye rs incubated in e it he r 3 mg/ml 
pemp higus lf(G (a,b) or ~~ mg/m l normal huma n lgG (c). Following 
incubation with co mple me nt , t.he ce ll s were s t ai ned with (a) FITC-goat 
a ntihuma n C lq, (b,c ) FITC-goat a ntihuman C3. Pos itive s t a ining (sp ec-
Ides) o n the surface o r t he ce ll s is ev iden t. in a a nd b, but not c. Original 
magnification x 625. 
organ and t issue culture skin cells in t hese experiments in an 
attempt to mimic acantholysis in vitro. Our content ion was 
that in areas of early-fo rming acantholysis, where cells are 
beginning to separate, more efficient fixation of complement 
might take place. Although some fix ation of complement by 
pemphigus ant ibody was observed using normal substrates 
(normal human skin and monkey esophagus), t he sta ining was 
less intense t han the sta ining of cu ltured epidermal cell s, and 
organ cul tured skin partially support ing this contention. Our 
posit ive findings a lso support t he reports of Nishikawa et al [9] 
and Hashimoto et a! [10] suggesting that at least some pem-
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FtG 2. Mouse epiderma l monolaye rs incubated in 3 mg/ml pemphi -
gus IgG . T he cells were then incubated in C2-delicient huma n serum 
a nd stained . a, FITC-goat antihuman Clq; b, FITC-go<~l ant1human C3. 
Positive sta ining (sper:ldes) on t he surface of the cells is evident in a, 
but not b. Ori gina l magnification x 625. 
phigus ant ibodies are capable of activating complement. 
As wit h bullous pemphigoid antibodies [17,18] and t he factor 
fo und in herpes gestationis sera. [1 9], the major pathway acti-
vated by pemphigus ant ibody is t he classical pathway. Signifi-
cant in vitro binding of Clq and C4 by pemphigus antibody was 
noted in both organ cul ture and tissue cul ture skin in addition 
TABLE I. In vitro complement staining reactions w£/h mouse 
epidermal mono/ayers and oruan cultured normal hum.an sl<in 
Reactionb 
Complement treatment" 
Clq C4 C3 
Pemphigus lgG NoC 
c ++ +++ +++ 
Purified Clq ++ 
C 5G"C for 30 min 
C p lus EDTA + 
C plus EGTA- Mg++ + + 
C2-deficien t. se rum ++ ++ 
C plus a nti-C3 ++ ++ 
Norma l huma n lgG No C 
c 
C2-deflcient se rum 
Sa line c 
"C: norma l huma n serum (complement source). 
b +: ;;peck led pattern in epidermal monolaye r cells or inte rcellula r 
sta inin g in orga n cu ltured skin and mucosa. Results obtai ned usin g 
epiderma l n10 n o la~'e r cells or organ cul tued sk in were identica l. 
F IG 3. Forty-e ight-hour adult human skin orga n culture in heat -
inac tivated norma l hu ma n seru m conta ining 6.75 mg/ ml pemphigus 
IgG. A rrows indicate Cl staining react ion in the intercellular areas. 
The epidermis depicted has separated from t he basal ce lls and the 
dermis. Origina l magnifica tion x 500. 
to C3. These in vitro findin gs a lso support previous direct IF 
studies where these same components have been found bound 
to ICS areas in pemphigus skin les ions [7,8]. Blockage of t he 
classical pathway by heat inactivation or addition of Mg++-
EGTA to t he complement source, or by substituting C2-defi-
cient serum as the complement source , inhibited the posit ive 
C3 sta ining. 
In addi t ion to direct IF studies, other findings have impli -
cated the complement system in t he pat hogenesis of pemphigus. 
Low levels of tota l hemolyt ic complement and individual com-
plement components have been noted in blister fluids of pem-
phigus pat ients, suggestive of local act ivation [20] . High-mo-
lecular-weight anticomplementa ry activity [21] and Clq binding 
activity [22] have also been detected in pemphigus sera and 
blister fluids, suggestive of immune complex formation. Fur-
ther , cryoprote ins, whic h contain lgG with pemphigus antibody 
and complemen t components, have been identified in sera of 
clinically active cases [23]. 
T he spec ific role that complement plays, if any, in the path-
ogenes is of pemphigus is presently unknown. Clea rly, pemphi-
gus antibody a lone is su ffici ent to initiate the process of aca n-
t holysis in vitro by organ culture methods [1 6] and to cause 
detachment of epidermal ce lls in culture and release of plas-
minogen activator [24,25]. Whether these processes are accel-
erated in the presence of complement must still be determined. 
T hese and othe r quest ions conce rning the invo lveP.1ent of the 
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complement system in pemphigus are currently being investi -
gated. 
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